Enhancing manufacturing consistency and clinical outcomes in cell-based immunotherapies

Cell-based immunotherapies, as a key subset of Advanced Therapy Medicinal Products (ATMPs), represent a rapidly evolving frontier in personalized medicine and cancer treatment. Despite notable breakthroughs, the translation of these therapies into widespread clinical success is constrained by significant manufacturing challenges, including variability in raw materials, processing conditions, and operator-dependent workflows. High-profile studies have highlighted how inconsistencies at every stage—from donor cell selection to gene modification, expansion, and formulation—can profoundly influence cellular phenotype, potency, persistence, and safety, ultimately shaping patient outcomes and the occurrence of adverse events. Furthermore, manufacturing complexity is compounded by reliance on critical materials, such as viral vectors and cytokines, whose variability and availability further restrict therapeutic reliability and scalability. Recent advances in automation, modular system design, process analytical technology (PAT), next-generation analytical tools, and digital manufacturing strategies are bridging some of these gaps, offering more robust and adaptive control over production. Yet, ongoing debates focus on the balance between innovation and standardization, with persistent questions about how best to ensure global comparability, cost-effectiveness, and accessibility. The need for comprehensive solutions that connect manufacturing rigor with clinical success remains urgent, especially as the therapeutic landscape grows more diverse and complex, encompassing both ex vivo and emerging in vivo platforms such as in vivo CAR-T therapies.This Research Topic aims to highlight and accelerate technological and scientific advances that confront the standardization bottlenecks of cell-based immunotherapy manufacturing. The main objective is to foster collaborative discussion and dissemination of innovative strategies that improve the consistency, potency, safety, and scalability, and cost-efficiency of therapeutic cell products. Central questions include which novel materials and vector systems can best reduce variability, how process innovations can enhance reproducibility, and which analytical and data-driven tools most reliably predict clinical performance. In particular, the Research Topic seeks to showcase solutions—for example, process automation, PAT and real-time monitoringrelease testing[SE1.1], phase-appropriate qualification of analytical QC assays, digital analytics, and harmonized comparability frameworks—that empower practitioners to deliver therapies that are not only effective but also reliable and accessible for broader patient populations. This[SE2.1] field extends to regulatory science, which delineates the challenges and opportunities intrinsic to concepts governing ATMP manufacturing. Presently, the regulatory framework for gene and cell therapies is experiencing a profound transition. A shift toward a risk-proportionate regulatory approach expedites the objective evaluation of novel cellular therapies, particularly in oncology, thus ultimately optimizing patient access.The scope of this Research Topic is focused on original and interdisciplinary research, reviews, and perspectives that address end-to-end manufacturing challenges across all cell-based immunotherapy platforms, including both ex vivo and in vivo approaches (e.g., in vivo CAR-T). It emphasizes innovative approaches and standardization strategies that measurably impact product quality and therapeutic outcomes, without being restricted to a single modality or process type. We welcome articles addressing, but not limited to, the following themes:• Development and implementation of novel materials, vectors, and delivery systems for improved efficacy and persistence• Advances in process automation, closed-system design, PAT technologies and real-time monitoring for reduced variability and cost• New analytical and potency assays that correlate with in vivo function and clinical safety• Frameworks for comparability and technology transfer in scale-up and multi-site manufacturing• Phase-appropriate qualification of analytical QC assays for early-phase clinical manufacturing• Integration of data-driven, AI/ML, and digital process analytics for process development and smarter, predictive manufacturing• Manufacturing-linked strategies to reduce immunogenicity, off-target effects, and adverse event profiles• Economic and operational models that optimize accessibility, cost efficiency, and product quality• Regulatory hurdles and opportunities in ATMP manufacturingProf. Stefan Eichmüller holds shares in FKT Fördergesellschaft für Krebs-Therapien mbH (Berlin) and will be employed by a non-profit spin-off of the University Hospital Heidelberg and the German Cancer Research Center (DKFZ). Topic editors: Carolina Kymie Nonaka, Stefan B Eichmüller, Jaichandran Sivalingam Source: https://www.frontiersin.org/research-topics/85943/enhancing-manufacturing-consistency-and-clinical-outcomes-in-cell-based-immunotherapies